BiomX (NYSEMKT:PHGE) Trading Down 2.3% – Here’s Why

BiomX Inc. (NYSEMKT:PHGE) traded down 2.3% on Tuesday . The stock traded as low as $0.93 and last traded at $0.94. 34,736 shares were traded during mid-day trading, a decline of 49% from the average session volume of 68,601 shares. The stock had previously closed at $0.96.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of BiomX in a report on Friday, August 16th.

BiomX Trading Down 2.3 %

The company has a debt-to-equity ratio of 0.51, a current ratio of 2.84 and a quick ratio of 2.84. The business’s 50-day moving average price is $1.11 and its two-hundred day moving average price is $2.48. The company has a market capitalization of $65.62 million, a price-to-earnings ratio of -1.54 and a beta of 1.29.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in BiomX stock. Ikarian Capital LLC bought a new position in shares of BiomX Inc. (NYSEMKT:PHGE) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 10,817,327 shares of the company’s stock, valued at approximately $4,868,000. Ikarian Capital LLC owned about 19.59% of BiomX as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 40.57% of the company’s stock.

About BiomX

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.